Related Experiment Video
Updated: May 10, 2026
12:00
Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles
Published on: January 22, 2015
Ultra-small and anionic starch nanospheres: formation and vitro thrombolytic behavior study
Yinjuan Huang1, Shenglong Ding, Mingzhu Liu
1Key Laboratory of Nonferrous Metal Chemistry and Resources Utilization of Gansu Province, State Key Laboratory of Applied Organic Chemistry and Department of Chemistry, Lanzhou University, Lanzhou 730000, PR China.
Carbohydrate Polymers
|June 18, 2013
Summary
This study introduces anionic starch nanospheres for controlled nattokinase (NK) delivery. These biocompatible nanospheres protect NK, prolonging its circulation and reducing bleeding risks.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Drug Delivery
Background:
- Nattokinase (NK) is a potent thrombolytic enzyme.
- Rapid biodegradation and short circulation time limit NK's therapeutic potential.
- Developing effective delivery systems for NK is crucial for its clinical application.
Purpose of the Study:
- To investigate the release of nattokinase (NK) from novel anionic starch nanospheres.
- To evaluate the characteristics, safety, and in vitro thrombolytic behavior of NK-loaded nanospheres.
Main Methods:
- Anionic starch nanospheres were synthesized using reverse micro-emulsion crosslinking.
- Characterization involved FTIR, SEM, TEM, and DLS.
- Cytotoxicity, biodegradability, and in vitro thrombolytic activity were assessed.
Main Results:
- Ultra-small, anionic starch nanospheres were successfully prepared.
- The nanospheres demonstrated non-toxicity, biocompatibility, and biodegradability.
- NK-loaded nanospheres protected NK from rapid biodegradation, prolonging in vivo circulation.
- A reduced thrombolysis rate was observed, potentially mitigating hemorrhage risks.
Conclusions:
- Anionic starch nanospheres represent a promising platform for nattokinase (NK) delivery.
- This system enhances NK stability and offers a safer therapeutic profile by controlling thrombolysis.
- Further in vivo studies are warranted to confirm therapeutic efficacy and safety.
